Jiangsu Hengrui Medicine Co., Ltd.

Shanghai Stock Exchange 600276.SS

Jiangsu Hengrui Medicine Co., Ltd. Interest Coverage Ratio for the year ending December 31, 2023: 713.19

Jiangsu Hengrui Medicine Co., Ltd. Interest Coverage Ratio is 713.19 for the year ending December 31, 2023, a 14.63% change year over year. Interest coverage ratio assesses earnings' ability to cover interest expenses; higher ratios signal lower risk.

Jiangsu Hengrui Medicine Co., Ltd. Interest Coverage Ratio for the year ending December 31, 2022 was 622.18, a -34.59% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. Interest Coverage Ratio for the year ending December 31, 2021 was 951.19, a -24.32% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. Interest Coverage Ratio for the year ending December 31, 2020 was 1,256.79, a 43.32% change year over year.
Jiangsu Hengrui Medicine Co., Ltd. Interest Coverage Ratio for the year ending December 31, 2019 was 876.88, a -7.07% change year over year.

Key data

Date	Interest Coverage Ratio	Debt to Equity Ratio	Interest Expense To Sales	Inventory Turnover Ratio

Shanghai Stock Exchange: 600276.SS

Jiangsu Hengrui Medicine Co., Ltd.

CEO	Mr. Hong Bin Dai
IPO Date	Oct. 18, 2000
Location	China
Headquarters	38 Huanghe Rd Eco & Tech Dev Park
Employees	19,611
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.

Key trends

Past 5 years